It’s only fair to share… Ozoralizumab Formula C1682H2608N472O538S12 CAS 1167985-17-2 Mol weight 38434.3245 PMDA JAPAN APPROVED 2022 2022/9/26 Nanozora anti-TNFα Nanobody®; ATN-103; Nanozora; PF-5230896; TS-152 Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. …
Category «Uncategorized»
Futibatinib
It’s only fair to share… Futibatinib フチバチニブ Formula C22H22N6O3 CAS 1448169-71-8 Mol weight 418.4485 2022/9/30 FDA APPROVED, Lytgobi Antineoplastic, Receptor tyrosine kinase inhibitor Disease Cholangiocarcinoma (FGFR2 gene fusion) 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one TAS-120, TAS 120, TAS120; Futibatinib Futibatinib, also known as TAS-120 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR …
ENOBOSARM
It’s only fair to share… Enobosarm Molecular FormulaC19H14F3N3O3 Average mass389.328 Da (2S)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide (2S)-3-(4-Cyanophénoxy)-N-[4-cyano-3-(trifluorométhyl)phényl]-2-hydroxy-2-méthylpropanamide 841205-47-8 [RN] GTx-024, MK 2866, Ostarine [Trade name] Enobosarm, also known as ostarine or MK-2866, is an investigational selective androgen receptor modulator (SARM) developed by GTx, Inc. for the treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company. Chemistry According to a 2009 paper authored by GTx, “Readers are cautioned to …
ELRAGLUSIB
It’s only fair to share… ELRAGLUSIB RN: 1034895-42-5 UNII: ND1SOF0DLU, WHO 11553, 9-ING-41 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)- 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione Antineoplastic Molecular Formula C22-H13-F-N2-O5 Molecular Weight 404.3517 OriginatorNorthwestern University; University of Illinois at Chicago DeveloperActuate Therapeutics; Incyte Corporation; Levine Cancer Institute; University of Kansas Medical Center ClassAntineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules Mechanism of ActionGlycogen synthase kinase 3 beta inhibitors Orphan …
Valemetostat tosilate
It’s only fair to share… Valemetostat tosilate バレメトスタットトシル酸塩 Formula C26H34ClN3O4. C7H8O3S CAS 1809336-93-3 Mol weight 660.2205 PMDA JAPAN approved 2022/9/26, Ezharmia 1,3-Benzodioxole-5-carboxamide, 7-chloro-N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-, (2R)-, compd. with 4-methylbenzenesulfonate (1:1) Antineoplastic, histone methyltransferase inhibitor 1809336-39-7 (free base). 1809336-93-3 (tosylate) 1809336-92-2 (mesylate) 1809336-94-4 (fumarate) 1809336-95-5 (tarate) Synonym: Valemetostat; DS-3201; DS 3201; DS3201; DS-3201b (2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide mono(4-methylbenzenesulfonate) C26H34ClN3O4▪C7H8O3S : 660.22 …
Gadopiclenol
It’s only fair to share… Gadopiclenol ガドピクレノール; Formula C35H54N7O15. Gd CAS 933983-75-6 Mol weight 970.0912 FDA APPROVED 2022/9/21, Elucirem Diagnostic agent (MR imaging), WHO 10744, P 03277, UNII: S276568KOY EluciremTM; G03277; P03277; VUEWAY (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium OriginatorGuerbet ClassDiagnostic agents; Gadolinium-containing contrast agents; Macrocyclic compounds; Propylamines; Pyridines Mechanism of ActionMagnetic resonance imaging enhancers RegisteredCNS disorders Phase IIIUnspecified Phase IILiver cancer 21 Sep …
LORPUCITINIB
It’s only fair to share… LORPUCITINIB JNJ 64251330 2230282-02-5 UNII-OE1QTY7C25 Molecular Weight 408.50 Formula C22H28N6O2 1-(TRANS-4-(CYANOMETHYL)CYCLOHEXYL)-1,6-DIHYDRO-N-(2-HYDROXY-2-METHYLPROPYL)IMIDAZO(4,5-D)PYRROLO(2,3-B)PYRIDINE-2-ACETAMIDE 2-[3-[4-(cyanomethyl)cyclohexyl]-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl]-N-(2-hydroxy-2-methylpropyl)acetamide is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. Lorpucitinib is an orally bioavailable pan-inhibitor of the Janus associated-kinases (JAKs), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, lorpucitinib works in the gastrointestinal (GI) tract …
Betibeglogene autotemcel
It’s only fair to share… Betibeglogene autotemcel ベチベグロゲンアウトテムセル 2022/8/17, FDA APPROVED Zynteglo Cellular therapy product Treatment of betathalassemia BB305 LVV, bb 1111 BB305 transduced SCD CD34+ HSCs bb1111 LentiGlobin BB305 LVV-transduced autologous SCD CD34+ HSCs bb1111 LentiGlobin drug product for SCD LentiGlobin drug product for sickle cell disease LentiGlobin for SCD bb1111 Betibeglogene autotemcel, sold under …
Lenacapavir sodium
It’s only fair to share… Lenacapavir sodium レナカパビルナトリウム Formula C39H31ClF10N7O5S2. Na C39H32ClF10N7O5S2 FREE FORM CAS 2283356-12-5 2189684-44-2 FEE FORM Mol weight 990.2641 968.28 FREE FORM 2022/8/17 EMA APPROVED, SUNLECA N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide Treatment of HIV-1 infection PF-3540074, to GS-CA1, GS-6207 GS-HIV GS-CA1 GS-CA2 Lenacapavir, sold under the brand name Sunlenca, is a medication used to treat HIV/AIDS.[1] It is taken by mouth or by subcutaneous injection.[1] …
ICENTICAFTOR
It’s only fair to share… QBW 251, ICENTICAFTOR Molecular FormulaC12H13F6N3O3 Average mass361.240 Da 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)- 3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-2-pyridinecarboxamide 3-Amino-6-méthoxy-N-(3,3,3-trifluoro-2-hydroxy-2-méthylpropyl)-5-(trifluorométhyl)-2-pyridinecarboxamide (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2- methylpropyl)-5-(trifluoromethyl)picolinamide 1334546-77-8 [RN] Icenticaftor (development code QBW251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD)[1][2] and cystic fibrosis.[3][4] The drug is being developed by Novartis.[5] Like ivacaftor (which is marketed as Kalydeco), icenticaftor functions by acting as a stimulator of the protein cystic fibrosis transmembrane conductance regulator (CFTR).[5] …